These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 11787956)

  • 1. Insidious dopamine: provocateur or protective agent in Parkinson's disease?
    Kostrzewa RM; Brus R; Kostrzewa JP
    Pol J Pharmacol; 2001; 53(2):165-6. PubMed ID: 11787956
    [No Abstract]   [Full Text] [Related]  

  • 2. Future therapies for Parkinson's disease.
    Hauser RA; Lyons KE
    Neurol Clin; 2004 Oct; 22(3 Suppl):S149-66. PubMed ID: 15501363
    [No Abstract]   [Full Text] [Related]  

  • 3. Recent advances in Parkinson's disease.
    Vécsei L
    Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
    [No Abstract]   [Full Text] [Related]  

  • 4. [The role of dopaminagonists in the treatment of Parkinson's disease].
    Ransmayr G
    Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment challenges in early stage Parkinson's disease.
    Tetrud J
    Neurol Clin; 2004 Oct; 22(3 Suppl):S19-33. PubMed ID: 15501364
    [No Abstract]   [Full Text] [Related]  

  • 6. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine dysregulation syndrome in Parkinson's disease: case report.
    Kummer A; Maia DP; Salgado JV; Cardoso FE; Teixeira AL
    Arq Neuropsiquiatr; 2006 Dec; 64(4):1019-22. PubMed ID: 17221016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Parkinson's disease. Advances in the pharmacological therapy.
    Ghika J
    Eur Neurol; 1996; 36(6):396-9. PubMed ID: 8954312
    [No Abstract]   [Full Text] [Related]  

  • 9. Neuroprotection for Parkinson's disease.
    Koller WC
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S155-9. PubMed ID: 9749588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
    Kostrzewa RM; Kostrzewa JP; Brus R
    Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa for the treatment of Parkinson's disease.
    Lewitt PA
    N Engl J Med; 2008 Dec; 359(23):2468-76. PubMed ID: 19052127
    [No Abstract]   [Full Text] [Related]  

  • 12. [Drug therapy of Parkinson's disease].
    Myllylä V
    Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076
    [No Abstract]   [Full Text] [Related]  

  • 13. Moderate Parkinson's disease. Strategies for maximizing treatment.
    Silverstein PM
    Postgrad Med; 1996 Jan; 99(1):52-4, 61-3, 67-8, passim. PubMed ID: 8539210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New directions in the drug treatment of Parkinson's disease.
    Montastruc JL; Rascol O; Senard JM
    Drugs Aging; 1996 Sep; 9(3):169-84. PubMed ID: 8877311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial agonist treatment of Parkinson disease: a critique.
    Albin RL; Frey KA
    Neurology; 2003 Feb; 60(3):390-4. PubMed ID: 12580185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment options for early Parkinson's disease.
    Stacy M; Brownlee HJ
    Am Fam Physician; 1996 Mar; 53(4):1281-7. PubMed ID: 8629572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease.
    Perez-Lloret S; Otero-Losada M; Toblli JE; Capani F
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1163-1173. PubMed ID: 28836869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relevance of preclinical studies for the treatment of Parkinson's disease.
    Gerlach M; Foley P; Riederer P
    J Neurol; 2003 Feb; 250 Suppl 1():I31-4. PubMed ID: 12761633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of selegiline as a neuroprotective agent in Parkinson's disease.
    Olanow CW; Mytilineou C; Tatton W
    Mov Disord; 1998; 13 Suppl 1():55-8. PubMed ID: 9613720
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline may be toxic in presence of increased dopamine concentrations.
    Yu PH; Lai CT; Boulton AA
    BMJ; 1996 Mar; 312(7032):703-4; author reply 704-5. PubMed ID: 8597749
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.